Venkat Thalladi serves as the senior vice president, CMC, at DICE Therapeutics. Prior to DICE, Venkat was at Theravance Biopharma for 12 years, most recently serving as the vice president and head of pharmaceutical development. At Theravance, Venkat contributed to 15 research and development programs ranging from preclinical to Phase 3 clinical products, as well as the marketed products YUPELRI® and VIBATIV®. Venkat led multiple drug product development programs at Theravance, which included solid orals, injectables, topicals, and nebulizer and dry powder inhaler products.
Prior to Theravance, Venkat was a principal investigator at XenoPort and an assistant professor in the department of chemistry and biochemistry at Worcester Polytechnic Institute.
Venkat holds a Ph.D. in chemistry from the University of Hyderabad and conducted postdoctoral work at the University of Essen and Harvard University.